TOT BIOPHARM International Co Ltd
HKEX:1875
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
CN |
T
|
TOT BIOPHARM International Co Ltd
HKEX:1875
|
1.7B HKD | 2.7 | |
US |
Abbvie Inc
NYSE:ABBV
|
295.2B USD | 9.5 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
165.2B USD | 11 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.5B USD | 13 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
110.4B USD | 9.1 | ||
AU |
CSL Ltd
ASX:CSL
|
139.9B AUD | 14.1 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
79.7B USD | 4.6 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
59.8B USD | 44.9 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 24.2 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
33.8B USD | 5.4 | ||
KR |
Celltrion Inc
KRX:068270
|
39.4T KRW | 36.9 |
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.